Alpha Tau Medical Ltd., (DRTS): Price and Financial Metrics
DRTS Price/Volume Stats
| Current price | $2.66 | 52-week high | $4.80 |
| Prev. close | $2.69 | 52-week low | $2.66 |
| Day low | $2.66 | Volume | 101,300 |
| Day high | $2.78 | Avg. volume | 31,817 |
| 50-day MA | $2.97 | Dividend yield | N/A |
| 200-day MA | $3.28 | Market Cap | 185.32M |
DRTS Stock Price Chart Interactive Chart >
Alpha Tau Medical Ltd., (DRTS) Company Bio
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest DRTS News From Around the Web
Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials - - The Company will also be featured at the Biotech Showcase™ occurring in parallel, and will host institutional investor meetings at both conferences - JERUSALEM, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or |
Sidoti Events, LLC's Virtual December Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ... |
Alpha Tau to Participate in Sidoti Small-Cap ConferenceJERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023. Format:Presentation and 1-on-1 meetingsDate:December 7th, 2023Time:9:15 AM ETLocation:VirtualRegistration:https://sidoti.zoom.us/webinar/register/WN_VNDWwCEtSeySoAVKVx38YQ About Al |
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increased tumor responses were observed, with the last three patients presenting two stable disease responses and one partial response at last measurement - JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical |
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck CancerJERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in pat |
DRTS Price Returns
| 1-mo | -9.83% |
| 3-mo | -12.79% |
| 6-mo | -19.64% |
| 1-year | -8.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.63% |
| 2023 | -5.35% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...